Platelet Count — Blood test measuring clotting cells

A platelet count measures the concentration of thrombocytes per microlitre of circulating blood, forming an integral component of a full blood count (FBC). Platelets are produced in the bone marrow from large cells called megakaryocytes and are essential for primary haemostasis. When blood vessel damage occurs, platelets rapidly adhere to the injury site, aggregate, and release chemical signals to establish a stable clot, preventing excessive blood loss.

A typical healthy adult platelet count ranges from 150,000 to 450,000 platelets per microlitre. In oncology, counts frequently fall below this reference range—a condition known as thrombocytopenia. This suppression occurs when cytotoxic anticancer treatments, radiation therapy, or marrow-infiltrating tumours impair normal haematopoiesis. Conversely, some malignancies cause abnormally elevated platelet levels (thrombocytosis), which may promote tumour progression and heighten thrombosis risk.

Monitoring your platelet count directly dictates the timing, dosing, and safety of cancer therapy. If your platelets drop significantly, doctors may need to delay chemotherapy cycles or reduce drug dosages to allow your bone marrow time to recover. Severe drops may necessitate platelet transfusions or supportive medications to prevent spontaneous haemorrhage. Awareness of your platelet count also prompts practical daily precautions, such as avoiding contact sports, using soft-bristled toothbrushes, and seeking prompt medical attention for unusual bruising or bleeding, keeping you safe throughout your therapeutic journey.

Platelet levels are measured via a routine venepuncture blood test as part of a full blood count (FBC) or complete blood count (CBC). Automated laboratory analysers count platelets and assess their average size (mean platelet volume). If results are borderline or abnormal, a manual peripheral blood smear may be examined under a microscope to confirm the count and rule out platelet clumping. Related tests include coagulation panels, such as prothrombin time (PT) and activated partial thromboplastin time (aPTT).

Platelet counts are routinely assessed across all cancers, but they are particularly crucial in haematological malignancies such as acute myeloid leukaemia, chronic lymphocytic leukaemia, multiple myeloma, and myelodysplastic syndromes, where the cancer directly invades the bone marrow. Platelet monitoring is equally essential for patients receiving intensive systemic chemotherapy or pelvic radiotherapy for solid tumours, including advanced breast, lung, ovarian, and colorectal cancers, where marrow suppression is a frequent, dose-limiting side effect.

Treatment regimens are directly calibrated to platelet counts. If counts fall below safe thresholds (often under 100,000 per microlitre), systemic chemotherapy or immunotherapy may be paused or dose-reduced. Minor surgical procedures and biopsies are routinely postponed until counts recover, typically above 50,000 per microlitre. In cases of severe thrombocytopenia (often below 10,000 to 20,000 per microlitre), prophylactic platelet transfusions or thrombopoietin receptor agonists may be administered to rapidly restore clotting capability.